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The St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer 
treatment. The main purpose of this article is to ascertain the clinical factors associated with St 
Gallen‑2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed 
with pathological stage < 3 in Spain between 2008 and 2013 was begun and then followed‑up until 
2017/2018. Data on patient and tumour characteristics were obtained from medical records, as well 
as their first line treatment. First line treatments were classified in three categories, according on 
whether they included the main St Gallen‑2013 recommendations, more than those recommended 
or less than those recommended. Multinomial logistic regression models were carried out to identify 
factors associated with this classification and Weibull regression models were used to find out the 
relationship between this classification and survival. About half of the patients were treated according 
to St Gallen recommendations; 21% were treated over what was recommended and 33% received less 
treatment than recommended. Factors associated with treatment over the recommendations were 
stage II (relative risk ratio [RRR] = 4.2, 2.9–5.9), cancer positive to either progesterone (RRR = 8.1, 
4.4–14.9) or oestrogen receptors (RRR = 5.7, 3.0–11.0). Instead, factors associated with lower 
probability of treatment over the recommendations were age (RRR = 0.7 each 10 years, 0.6–0.8), poor 
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differentiation (RRR = 0.09, 0.04–0.19), HER2 positive (RRR = 0.46, 0.26–0.81) and triple negative 
cancer (RRR = 0.03, 0.01–0.11). Patients treated less than what was recommended in St Gallen had 
cancers in stage 0 (RRR = 21.6, 7.2–64.5), poorly differentiated (RRR = 1.9, 1.2–2.9), HER2 positive 
(RRR = 3.4, 2.4–4.9) and luminal B‑like subtype (RRR = 3.6, 2.6–5.1). Women over 65 years old had 
a higher probability of being treated less than what was recommended if they had luminal B‑like, 
HER2 or triple negative cancer. Treatment over St Gallen was associated with younger women and 
less severe cancers, while treatment under St Gallen was associated with older women, more severe 
cancers and cancers expressing HER2 receptors.
From 1995 on, many relevant advances in early breast cancer (BC) treatment have contributed to the improve-
ment in patient survival. For instance, the emergence of  anthracycline1 and taxane-based  therapies2 and the 
identification of intrinsic  subtypes3. Several guidelines for treating breast cancer patients have been published, 
although their recommendations differ only  marginally4. In this regard, the 12th and 13th St Gallen International 
Breast Cancer Conference Expert Panel took place in 2011 and 2013, respectively; it endorsed a series of recom-
mendations on early BC  treatment5,6. We hereby briefly summarize St Gallen-2013 recommendations according 
to BC subtypes that are almost identical to those formulated in the previous meeting. Firstly, the Conference 
agreed in a clinico-pathological surrogate definition of intrinsic BC subtypes and secondly, the Conference stated 
systemic treatment recommendations for each subtype. In this regard, patients with luminal A-like BC should be 
treated with endocrine therapy, although cytotoxics may be added in the case of selected patients. Patients with 
luminal B-like (HER2 negative) BC should be treated with endocrine therapy and cytotoxics should be added 
for most of them. Patients with luminal B-like (HER2 positive) BC should receive cytotoxics, anti-HER2 and 
endocrine therapy; patients with HER2 positive (non-luminal) BC should receive cytotoxics and anti-HER2 and 
patients with triple negative (basal-like) BC should be treated with cytotoxics. It is noteworthy, that St Gallen 
panel was not unanimous in most of its decisions and it remarked that its recommendations were not just a blind 
guide; instead, “detailed decisions on treatment will, as always, involve clinical considerations of disease extent, 
host factors, patient preferences and social and economic constraints”5.
Several studies have shown adherence to guidelines for early stage BC diverged between  countries7 and 
tumour characteristics; triple negative breast  cancer7,8 and hormone receptors-negative HER2  positive9 being 
the subgroups with lower adherence. Older women are more likely to receive non-guideline adherent treatment 
leading to poorer survival  rates7,10,11. Socio-economic status has been found to be associated to differences in 
guideline compliance in the  US12–14 and to less extent in The  Netherlands15.
The MCC-Spain breast cancer cohort recruited 1738 women with recent diagnosis of breast cancer in ten 
Spanish provinces between 2008 and 2013, which were subsequently followed-up until 2017 and 2018. In this 
paper, our objectives are: (1) to ascertain the clinical factors associated with St Gallen-2013 recommendations 
accomplishment, (2) to investigate whether there are differences by age and intrinsic BC subtype regarding St 
Gallen fulfilment, and (3) to examine the impact St Gallen non-fulfilment may have on survival with breast 
cancer. As most women in MCC-Spain were recruited before the 13th St Gallen Conference, St Gallen recom-
mendations cannot be interpreted as a gold standard; therefore, our purpose is not to perform an audit but to 
identify patterns in actual clinical practice.
Methods
MCC‑Spain BC cohort: setting and patients. MCC-Spain was born as a case–control study on colorec-
tal, breast, prostate and gastric cancers and chronic lymphoid  leukaemia16. Later on, the colorectal, breast and 
prostate cancer cases recruited in the case–control phase were incepted in three cancer-specific cohorts in order 
to ascertain clinical, genetic and epidemiological factors associated with  prognosis17. From here on, we only refer 
to the breast cancer cohort.
This research was performed according to the standards required by the institutional research committees 
and the Declaration of Helsinki (last amendment, Fortaleza, 2013). The protocol of MCC-Spain was approved by 
each of the ethics committees of the participating  institutions16. The specific study reported here was approved 
by the Ethical Committee of Clinical Research of Asturias, Barcelona, Cantabria, Girona, Gipuzkoa, Huelva, 
León, Madrid, Navarra and Valencia. Informed consent was obtained from all individual participants included 
in the study.
Women were included in the study cohort if they suffered an incident of pathologically confirmed breast 
cancer in the 2008–2013 period. After signing an informed consent, 1738 women were recruited in ten Span-
ish provinces (Asturias, Barcelona, Cantabria, Gipuzkoa, Girona, Huelva, León, Madrid, Navarra y Valencia) 
and were interviewed by trained personnel in order to gather demographic and epidemiological  information17. 
Women with breast cancer in stages 0, I or II were included in this analysis (1214 patients).
Tumour characteristics. Tumour characteristics at diagnosis were obtained from medical records. They 
included grade of differentiation (I: well, II: moderately, III: poorly differentiated), histological type (ductal, 
lobular, papillary, others), pathological stage according to TNM, presence or absence of oestrogen receptors, 
progesterone receptors and HER2 receptors, as well as other immunohistochemical properties when available 
(Ki-67, for instance)17. Intrinsic subtypes were determined according to St Gallen clinico-pathological surrogate 
definitions (Supplementary Table 1). A tumour was considered luminal A-like if it had positive oestrogen and 
progesterone receptors, HER2 negative and Ki-67 low. In this regard, tumours without Ki-67 determination were 
considered Ki-67 low for classification purposes if it was grade I or II, and Ki-67 high if it was grade III, as grade 
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III is indicative of high proliferative activity, according to Curigliano et al.18. A tumour was classified as luminal 
B-like if (1) it had positive oestrogen receptors, HER2 negative and Ki-67 high or negative progesterone receptor 
or (2) positive oestrogen receptors and positive HER2. A cancer was considered HER2 positive (non-luminal) if 
it was oestrogen and progesterone receptors negative and HER2 receptors positive. Finally, tumours with oestro-
gen, progesterone and HER2 receptors negative were classified as triple negative.
First‑line treatment. Data on first-line treatment was obtained from medical records. They could include 
type of surgery (conservative/mastectomy), endocrine therapy, chemotherapy, anti-HER2 therapy or radiother-
apy. Treatments other than surgery were classified as neoadjuvant, adjuvant or palliative, according to their 
purpose.
Classification according to St Gallen‑2013. First-line systemic treatments were classified into three 
groups (In-, Over- and Under St Gallen) according to the adherence to St Gallen-2013 recommendations as 
follows.
– In St Gallen: A treatment was considered “In St Gallen” if it consisted in exactly the main St Gallen recom-
mendation for that patient (Supplementary Table 1). For instance, a woman with breast cancer oestrogen-
receptor positive, progesterone-receptor positive and HER2 negative receiving just surgical treatment + endo-
crine therapy.
– Over St Gallen: A treatment was considered “Over St Gallen” if the woman received the main St Gallen recom-
mendation for her cancer plus some additional therapy. For instance, a woman with breast cancer oestrogen-
receptor positive, progesterone-receptor positive and HER2 negative receiving surgical treatment + endocrine 
therapy + anti-HER2 therapy.
– Under St Gallen: A treatment was considered “Under St Gallen” if the woman did not receive the main St 
Gallen recommendation for her cancer (in spite of whether she received additional treatments included in 
the main recommendation or not). For example, a woman with breast cancer oestrogen-receptor positive, 
progesterone-receptor positive and HER2 negative receiving surgical treatment + chemotherapy, but not 
endocrine therapy.
In order to analyse the reliability of the above indicated classification, two independent evaluators (MM and 
JA-M) applied it to a randomly selected 50-woman subsample, reaching a Cohen’s kappa = 0.76.
Follow-up for ascertaining the vital status was carried out in 2017 and 2018 by reviewing medical records, 
contacting women by phone and for women without contact with the hospital in the previous three months, by 
consulting the Spanish National Index of Death.
Statistical analysis. The association between age or tumour characteristics and St Gallen fulfilment was 
analysed using multinomial logistic regression as the effect variable (St Gallen) has three categories; results—
adjusted for age at diagnosis and hospital—are presented as relative risk ratios (RRR) with 95% confidence inter-
vals. Overall survival is presented using Kaplan–Meier estimators. The association of St Gallen fulfilment and 
survival was analysed separately for each intrinsic subtype using Weibull regression adjusted for age at diagnosis, 
hospital, grade of differentiation and pathological stage. Weibull regression was considered adequate as the rela-
tionship between log[− log(survival probability)] and log(time of follow-up) was approximately linear. For this 
analysis, event was defined as death and patients were censored if they were alive at the end of follow-up. Weibull 
regression results are presented as hazard ratios (HR) with 95% confidence intervals. A complementary Weibull 
analysis was carried out where the event was distant recurrence or dead (the first that happened); patients alive 
and without distant recurrence at the end of follow-up were considered censored. All statistical analyses were 
performed with the Stata 16/SE software (Stata Co., College Station, Tx, US).
Results
The study sample is described in Table 1 and the patient flow chart in Fig. 1. Out of 1242 breast cancers in stages 
0, I or II, intrinsic subtype was established in 1152 cases; luminal A-like was the most frequent subtype (687 
cases, 60%), 324 cases (28%) were luminal B-like, 52 (5%) were HER2 (non-luminal) and 89 (8%) were triple 
negative. The intrinsic breast cancer subtype could not be determined in 90 cases (7%). 56 were hormonal recep-
tors positive, but results on HER2 receptor were not available. Therefore, they could be classified as luminal, 
but we could not ascertain if they were luminal A or luminal B. Eight cases were hormonal receptors negative, 
but—again—results on HER2 receptors were not available. Therefore, those cases were non-luminal, but we 
could not determine if they were HER-2 positive or triple negative. In 26 cases, we had no data on hormonal 
or HER2 receptors. Recurrence in the follow-up was found in 86 women (7.5%), 52 of them being distant. 94 
(8.9%) women died in the follow-up.
Out of 1152 breast cancer cases with established intrinsic subtype, 523 (45.4%) were treated In St Gallen, 
243 (21.1%) Over St Gallen and 386 (33.5) Under St Gallen. Over St Gallen was more frequent in patients with 
luminal A cancer (219 out of 687 cases, 31.9%) and Under St Gallen was more frequent in patients with luminal 
B cancer (173 out of 324 cases, 53.4%) (Table 2).
Table 3 provides the factors associated with Over St Gallen treatment. Women with breast cancer in stage II 
had more than four times the probability of being treated Over St Gallen (RRR = 4.15, 95% CI 2.90–5.94) com-
pared to women with breast cancer in stage I. Cancers positive to either progesterone or oestrogen receptors 
also increased the likelihood of treatment Over St Gallen. Factors associated with lower probability of being 
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treated Over St Gallen were age (RRR = 0.70, 95% CI 0.62–0.81 for each 10 years more), poorly differentiated 
cancers (RRR = 0.09, 95% CI 0.04–0.19), HER2 positive cancers (RRR = 0.46, 95% CI 0.26–0.81) and luminal 
B and triple negative subtypes (RRR = 0.07, 95% CI 0.04–0.13 and RRR = 0.03, 95% CI 0.01–0.11, respectively.) 
Regarding differences according to age by tumoral subtype, women over the age of 65 had a lower probability of 
being treated Over St Gallen if they had luminal A-like cancer than those under 65 (Fig. 2a).
Under St Gallen treatment was more frequent in patients with pathological stage 0 (RRR = 21.6, 95% CI 
7.221–64.5), poorly differentiated cancer (RRR = 1.88, 95% CI 1.21–2.93) or missing grade of differentiation 
(RRR = 3.72, 95% CI 2.21–6.29), cancers positive to HER2 receptors (RRR = 3.44, 95% CI 2.40–4.93) and luminal 
B and HER2 intrinsic subtypes (RRR = 3.63, 95% CI 2.59–5.09 and RRR = 4.38, 95% CI 2.23–8.60, respectively) 
(Table 4). Compared with women under 65, those 65 years or over had a higher probability of being treated Under 
St Gallen if they suffered a luminal B-like, Her2 (non-luminal) or triple negative cancer (Fig. 2b).
The follow-up accounted for 7730 patient-years. 94 women died in the follow-up, making a linearized mor-
tality rate of 1.22 per 100 patient-years (95% CI 0.98–1.49). Crude 5-year overall survival was 94.2%; survival at 
5 years was approximately equal for patients treated In St Gallen and Under St Gallen and about 4% higher for 
patients Over St Gallen (Table 5, Fig. 3). After adjusting for age, hospital, grading and stage at diagnosis, Under 
St Gallen treatment was associated with a higher probability of dying in women with triple negative breast cancer 
(HR = 4.65, 95% CI 0.87–24.8), but not in other breast cancer subtypes (Suppl. Table 2). Results from Weibull 
regression using the combined event distant recurrence or dead (Suppl. Table 3) were similar to those founded 
for overall survival (Suppl. Table 2).
Discussion
According to our results, systemic treatment of early breast cancer fully accomplished St Gallen-2013 recom-
mendations in about 50% patients; two out of nine were treated Over St Gallen and three in ten were treated 
Under St Gallen. This variability was related to both age and tumour characteristics. Regarding age, older women 
tended to have less likelihood of being treated Over St Gallen (30% lower probability each ten years) and more 
Table 1.  Description of the 1152 patients included in the sample.
Variable Category N (%)
Age (mean ± sd) 56.2 ± 12.2
Age
< 65 864 (75.0)
≥ 65 288 (25.0)
Grade of differentiation
I (well differentiated) 260 (22.6)
II (moderately differentiated) 367 (31.9)
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likelihood, although non-statistically significant- to be treated Under St Gallen (8% higher probability each ten 
years). Altogether, more severe tumours (stage II, poorly differentiated, hormone receptors negative, basal-like) 
were less likely to be treated Over St Gallen. Most severity factors, except triple negative tumour, were associated 
with higher probability of being treated Under St Gallen.
Interpreting these results is not straightforward. First of all, St Gallen recommendations were not just a 
“must”. Instead, they should have been individualized in the light of both patient and clinical information. In 
this regard, further St Gallen International Breast Cancer Conferences have focused on a practical approach of 
therapies to individual  patients19 as well as identifying patients that could benefit from escalating or de-escalating 
 treatments18. Our results cannot be interpreted as an audit of accomplishing clinical guides as patients in our 
cohort were recruited from 2008 to 2013 (i.e., before St Gallen recommendations were stated); instead, our 
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Table 2.  Description of St Gallen fulfilment/non-fulfilment according to breast cancer intrinsic subtypes. 
a Percentages refer to each intrinsic subtype.
Intrinsic subtype St Gallen fulfilment Reason of non-fulfilment n (%)a
Luminal A-like (n = 687)
In St Gallen 298 (43.4)
Over St Gallen
Neoadjuvant + adjuvant chemotherapy 1 (0.1)
Chemotherapy 220 (32.0)
Under St Gallen
Lack of endocrine therapy 156 (22.7)
Lack of chemotherapy 12 (1.7)
Luminal B-like (n = 324)
In St Gallen 139 (42.9)
Over St Gallen Neoadjuvant + adjuvant chemotherapy 12 (3.7)
Under St Gallen
Lack of endocrine therapy 48 (14.8)
Lack of chemotherapy 54 (16.7)
Lack of anti-HER2 therapy 17 (5.3)
Lack of chemotherapy and endocrine therapy 1 (0.5)
No systemic treatment recorded 54 (16.7)
HER2 positive (non-luminal) (n = 52)
In St Gallen 17 (32.7)
Over St Gallen Neoadjuvant + adjuvant chemotherapy 7 (13.5)
Under St Gallen
Lack of chemotherapy 1 (1.9)
Lack of anti-HER2 therapy 13 (44.8)
No systemic treatment recorded 14 (26.9)
Triple negative (ductal) (n = 89)
In St Gallen 69 (77.5)
Over St Gallen
Anti-Her2 therapy 1 (1.1)
Endocrine therapy 2 (2.3)
Under St Gallen Lack of chemotherapy 17 (19.1)
Total (n = 1152)
In St Gallen 523 (45.4)
Over St Gallen 243 (21.1)
Under St Gallen 386 (33.5)
Table 3.  Tumour characteristics associated with “Over St Gallen” treatment. Relative risk ratios (RRR) are 
adjusted for age at diagnosis and hospital of recruitment.
Variable Category n Over St Gallen/n included RRR (95% CI) p
Age (each 10 years) 0.70 (0.62–0.81) < 0.001
Pathological stage
0 0/36 – –
I 56/519 1 (ref.) –
II 187/597 4.15 (2.90–5.94) < 0.001
Grade of differentiation
I (well differentiated) 69/260 1 (ref.) –
II (moderately differentiated) 115/367 1.26 (0.84–1.89) 0.27
III (poorly differentiated) 10/222 0.09 (0.04–0.19) < 0.001
Missing 49/303 1.03 (0.55–1.92) 0.94
Histological type
Ductal 200/918 1 (ref.) –
Lobular 20/82 1.72 (0.94–3.17) 0.08
Papilar 1/16 0.31 (0.04–2.53) 0.28
Others 22/136 0.87 (0.50–1.50) 0.61
Progesterone receptors
Negative 14/262 1 (ref.) –
Positive 229/887 8.12 (4.41–14.9) < 0.001
Missing 0/3 – –
Oestrogen receptors
Negative 12/155 1 (ref.) –
Positive 231/996 5.71 (2.97–11.0) < 0.001
Missing 0/1 – –
HER2 receptors
Negative 224/953 1 (ref.) –
Positive 19/199 0.46 (0.26–0.81) 0.007
Intrinsic subtype
Luminal A-like 221/687 1 (ref.) –
Luminal B-like 12/324 0.07 (0.04–0.13) < 0.001
HER2 positive (non-luminal) 7/52 0.30 (0.11–0.83) 0.02
Triple negative (ductal) 3/89 0.03 (0.01–0.11) < 0.001
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Figure 2.  Relative risk ratios (RRR) for women over 65 years old compared with women under 65 years old of 
being treated Over (a) or Under (b) St Gallen. In (a), RRR > 1 indicates that women over 65 were more likely to 
be treated Over St Gallen than women under 65 years old, while in (b), RRR > 1 indicates that women over 65 
were more likely to be treated Under St Gallen than women under 65. Results on HER2 + tumours treated Over 
St Gallen are not shown as analysis did not converge.
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comparison of actual treatments with St Gallen is a portrayal on the way breast cancer patients were treated as 
compared to the state-of-the-art about the same time.
Apart from St Gallen recommendations, several organizations have delivered their own guidelines on breast 
cancer  treatment20,21, although they usually differ only  marginally4. A main factor related with deviations from 
guidelines is woman’s age. Several studies have described that older women are less likely to receive or be offered 
standard  treatment10,11,22–24, leading to be given adjuvant chemotherapy less  frequently25,26. Regarding endocrine 
therapy, between-countries large variation has been observed in women over 70 years old, without variation in 
relative survival, which suggests possible  overtreatment27; women under 50 have been found less adherent to 
endocrine  therapy28. According to our results, treatment in Spanish women with breast cancer differed between 
those over and under 65 years of age. The latter being less prone to be treated Over St Gallen if suffering luminal 
Table 4.  Tumour characteristics associated with “Under St Gallen” treatment. Relative risk ratios (RRR) are 
adjusted for age at diagnosis and hospital of recruitment.
Variable Category n Under St Gallen/n included RRR (95% CI) p
Age (each 10 years) 1.08 (0.06–1.21) 0.21
Pathological stage
0 32/36 21.6 (7.21–64.5) < 0.001
I 172/519 1 (ref.) –
II 182/597 1.34 (1.00–1.78) 0.05
Grade of differentiation
I (well differentiated) 61/260 1 (ref.) –
II (moderately differentiated) 97/367 1.38 (0.91–2.09) 0.13
III (poorly differentiated) 84/222 1.88 (1.21–2.93) 0.005
Missing 144/303 3.72 (2.21–6.29) < 0.001
Histological type
Ductal 288/918 1 (ref.) –
Lobular 31/82 1.40 (0.82–2.41) 0.22
Papilar 5/16 0.72 (0.23–2.25) 0.57
Others 62/136 1.96 (1.28–2.99) 0.002
Progesterone receptors
Negative 110/262 1 (ref.) –
Positive 275/887 0.67 (0.49–0.94) 0.02
Missing 1/3 0.67 (0.06–7.86) 0.75
Oestrogen receptors
Negative 51/155 1 (ref.) –
Positive 335/996 1.13 (0.76–1.67) 0.54
Missing 0/1 – –
HER2 receptors
Negative 272/953 1 (ref.) –
Positive 114/199 3.44 (2.40–4.93) < 0.001
Intrinsic subtype
Luminal A-like 168/687 1 (ref.) –
Luminal B-like 173/324 3.63 (2.59–5.09) < 0.001
HER2 positive (non-luminal) 28/52 4.38 (2.23–8.60) < 0.001
Triple negative (ductal) 17/89 0.70 (0.39–1.28) 0.25
Table 5.  Crude Kaplan–Meier estimated survival probabilities according to St Gallen adherence and age at 
diagnosis. a Event: dead. Censored: patients alive at the end of follow-up. b Event: dead or distant recurrence. 
Censored: patients alive and without distant recurrence at the end of follow-up.
St Gallen adherence 5-year overall survival  probabilitya
5-year survival probability without distant 
 recurrenceb
Whole sample
In St Gallen 93.0 (90.4–94.9) 91.5 (88.7–93.6)
Over St Gallen 97.1 (94.0–98.6) 96.7 (93.4–98.3)
Under St Gallen 93.1 (90.0–95.2) 92.6 (89.4–94.8)
Total 94.2 (92.7–95.4) 92.9 (91.3–94.3)
Age < 65
In St Gallen 94.9 (92.1–96.7) 93.3 (90.3–95.4)
Over St Gallen 97.6 (94.3–99.0) 97.1 (93.7–98.7)
Under St Gallen 96.3 (93.2–98.0) 95.9 (92.7–97.7)
Total 96.3 (94.9–97.3) 95.1 (93.4–96.3)
Age ≥ 65
In St Gallen 88.1 (81.5–92.4) 86.7 (79.9–91.3)
Over St Gallen 93.6 (76.6–98.4) 93.6 (76.6–98.4)
Under St Gallen 84.9 (76.6–90.5) 84.0 (75.6–89.8)
Total 86.7 (82.0–90.3) 86.4 (81.8–86.4)
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A-like and more prone to be treated Under St Gallen if suffering any other intrinsic breast cancer subtype (luminal 
B-like, Her2 non-luminal or triple negative), meaning that in all subtypes, women over 65 received less treatment 
on average. There are several issues regarding recommendations for treating early breast cancer in women over 
65 or 70; firstly, breast cancers in older women tend to be less  aggressive29. Secondly, older women are usually 
under-represented in clinical  trials30,31, which makes it more difficult to establish standards for treating these 
 patients32. Thirdly, Spanish women aged 65 and 70 have life expectancy of 23.0 and 18.7 years,  respectively33; 
therefore, short expectancy of life cannot be argued for supporting undertreatment.
Women with luminal A-like tumours were more probably treated Over St Gallen than women with any other 
intrinsic subtype. In this regard, the main Over St Gallen treatment in women with luminal A-like tumours 
was chemotherapy. Whether hormone-positive, HER2-negative and node-negative patients would benefit from 
chemotherapy remains controversial; a 21-gene score (Oncotype DX, Genomic Health, Redwood City, CA) has 
been proven to have predictive value for  recurrence34,35 and has been endorsed by several scientific  societies20,21. 
TAILORx trial has shown that women scoring Oncotype DX ≤ 25 can receive hormone therapy alone, while 
women scoring > 25 should benefit from adjuvant  chemotherapy36,37. By the time our patients were recruited, 
genetic testing was not of general use. However, it has been recently shown that combining information from 
age, tumour size, grading, progesterone receptors and histological type can establish risk of recurrence as from 
Oncotype  DX38. When applying Orucevic et al. model to our patients, only one in ten women receiving chemo-
therapy against luminal A-like tumour had a probability higher than 20% of having a high risk of recurrence, 
which suggests most of them had been over treated (results not shown).
Our results could imply some clinical considerations. First of all, St Gallen recommendations, as well as 
guidelines issued by other  organizations20,21, could inform about treatment of patients with BC, although clini-
cians should take decisions on an individual basis. In this regard, the trend we describe towards less aggressive 
treatment in older women is noteworthy. Such a conservative decision could not be justified by general considera-
tions (e.g., expectancy of life in older women), but on specific individual grounds (e.g., comorbidities or other 
factors limiting patient’s benefit). Secondly, the idea of BC being a homogenous disease requiring homogenous 
treatment is largely outdated. However, we lay out the fact that less aggressive BC tend to be treated over the 
standard recommendations while those that are more aggressive are treated under the recommendations, which 
makes treatment of biologically different BC as if they were alike. The clinical consequences of it would require 
further research.
Our study has some limitations. Firstly, our classification on St Gallen recommendation accomplishment is 
somewhat subjective; we have found the between-raters reliability to be high, but there is still room for misclas-
sification. Secondly, less severe cancers usually require less treatment and so, are more likely to be Over St Gallen, 
while more severe cancers require more treatment and are more likely to be Under St Gallen. Thirdly, our follow-
up is still short as 5-year survival in early BC is around 90%. Fourthly, comorbidities were not recorded, which 
may affect whether clinical guidelines are closely followed or not. In fifth place, our number of patients—although 
Figure 3.  Crude Kaplan–Meier estimates of overall survival probability according to St Gallen fulfilment. Five-
year survival probabilities were 97.1 for women treated over St Gallen, 93.1 for women treated under St Gallen 
and 93.0 for women treated in St Gallen.
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high for general analysis—was not enough to study interactions or to analyse the effect of St Gallen unfulfillment 
in depth. In this regard, several results of our survival analysis are based on small figures (Suppl. Table 2), which 
makes them little reliable. Our study also has some strengths. Firstly, information on more than one thousand 
patients was obtained in a standardized way without acknowledgment of this paper’s hypothesis; therefore, 
misclassification on clinical characteristics or first-line treatment could only introduce a non-differential bias. 
Secondly, follow-up was performed prospectively, which guarantees high quality follow-up data.
In conclusion, about 50% women with early BC were treated according to St Gallen recommendations. 
Treatment Over St Gallen was associated with younger women and less severe cancers (luminal A-like, well-
differentiated, stage I) and treatment Under St Gallen was associated with older women, more severe cancers 
and cancers expressing HER2 receptors. No differences in overall survival were observed between the Under St 
Gallen group compared to the adherent group, which implies that there were no great deviations from “standard” 
treatment in our context. Finally, the improvement in survival observed in the Over St Gallen group supports 
the decision taken by the medical team treating these patients.
Received: 19 March 2020; Accepted: 20 January 2021
References
 1. Clarke, M. et al. Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An 
Overview of the Randomised Trials (Centre for Reviews and Dissemination, 2005).
 2. Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273–1283 (2011).
 3. Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. 
Acad. Sci. USA 98, 10869–10874 (2001).
 4. Wolters, R. et al. A comparison of international breast cancer guidelines—Do the national guidelines differ in treatment recom-
mendations?. Eur. J. Cancer 48, 1–11 (2012).
 5. Goldhirsch, A. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert 
Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 24, 2206–2223 (2013).
 6. Goldhirsch, A. et al. Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen International 
Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22, 1736–1747 (2011).
 7. Schwentner, L. et al. Adherence to treatment guidelines and survival in triple-negative breast cancer: A retrospective multi-center 
cohort study with 9156 patients. BMC Cancer 13, 487 (2013).
 8. Schwentner, L. et al. Triple-negative breast cancer: The impact of guideline-adherent adjuvant treatment on survival—A retrospec-
tive multi-centre cohort study. Breast Cancer Res. Treat. 132, 1073–1080 (2012).
 9. Ebner, F. et al. Tumor biology in older breast cancer patients—What is the impact on survival stratified for guideline adherence? 
A retrospective multi-centre cohort study of 5378 patients. The Breast 24, 256–262 (2015).
 10. Bastiaannet, E. et al. Breast cancer in elderly compared to younger patients in the Netherlands: Stage at diagnosis, treatment and 
survival in 127,805 unselected patients. Breast Cancer Res. Treat. 124, 801–807 (2010).
 11. Malik, M. K., Tartter, P. I. & Belfer, R. Undertreated breast cancer in the elderly. J. Cancer Epidemiol. https ://www.hinda wi.com/
journ als/jce/2013/89310 4/. (2013). https ://doi.org/10.1155/2013/89310 4.
 12. Griggs, J. et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J. Clin. Oncol. Off. J. 
Am. Soc. Clin. Oncol. 25, 2522–2527 (2007).
 13. Wu, T.-Y. et al. Admission rates and in-hospital mortality for hip fractures in England 1998 to 2009: time trends study. J. Public 
Health (Oxf.) 33, 284–291 (2011).
 14. Dreyer, M. S., Nattinger, A. B., McGinley, E. L. & Pezzin, L. E. Socioeconomic status and breast cancer treatment. Breast Cancer 
Res. Treat. 167, 1–8 (2018).
 15. Kuijer, A. et al. The influence of socioeconomic status and ethnicity on adjuvant systemic treatment guideline adherence for early-
stage breast cancer in the Netherlands. Ann. Oncol. 28, 1970–1978 (2017).
 16. Castaño-Vinyals, G. et al. Population-based multicase-control study in common tumors in Spain (MCC-Spain): Rationale and 
study design. Gac. Sanit. 29, 308–315 (2015).
 17. Alonso-Molero, J. et al. Cohort profile: The MCC-Spain follow-up on colorectal, breast and prostate cancers: Study design and 
initial results. BMJ Open 9:e031904. https ://doi.org/10.1136/bmjop en-2019-03190 4 (2019).
 18. Curigliano, G. et al. De-escalating and escalating treatments for early-stage breast cancer: The St Gallen International Expert 
Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann. Oncol. 28, 1700–1712 (2017).
 19. Coates, A. S. et al. Tailoring therapies—Improving the management of early breast cancer: St Gallen International Expert Consensus 
on the Primary Therapy of Early Breast Cancer 2015. Ann. Oncol. 26, 1533–1546 (2015).
 20. Harris, L. N. et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast 
cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 34, 1134–1150 (2016).
 21. Gradishar, W. J., et al. guidelines index table of contents discussion. Breast Cancer 216 (2019). Breast Cancer, Version 3.2020, NCCN 
Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw., 18(4), 452–478. https ://doi.org/10.6004/jnccn .2020.0016 
(2020).
 22. Bouchardy, C., Rapiti, E., Blagojevic, S., Vlastos, A.-T. & Vlastos, G. Older female cancer patients: Importance, causes, and con-
sequences of undertreatment. J. Clin. Oncol. 25, 1858–1869 (2007).
 23. Lavelle, K. et al. Non-standard management of breast cancer increases with age in the UK: A population based cohort of women 
≥ 65 years. Br. J. Cancer 96, 1197–1203 (2007).
 24. Guevara, M. et al. Care patterns and changes in treatment for nonmetastatic breast cancer in 2013-2014 versus 2005: a population-
based high-resolution study. Eur J Cancer Prev. 26 Joining forces for better cancer registration in Europe:S215–S222. (2017) https 
://doi.org/10.1097/CEJ.00000 00000 00037 9 (2017).
 25. DeMichele, A., Putt, M., Zhang, Y., Glick, J. H. & Norman, S. Older age predicts a decline in adjuvant chemotherapy recommenda-
tions for patients with breast carcinoma. Cancer 97, 2150–2159 (2003).
 26. Ring, A. et al. The treatment of early breast cancer in women over the age of 70. Br. J. Cancer 105, 189–193 (2011).
 27. Derks, M. G. M. et al. Variation in treatment and survival of older patients with non-metastatic breast cancer in five European 
countries: A population-based cohort study from the EURECCA Breast Cancer Group. Br. J. Cancer 119, 121–129 (2018).
 28. Font, R. et al. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: A population-based study 
in Catalonia, Spain. Breast Cancer Res. Treat. 175, 733–740 (2019).
 29. Diab, S. G., Elledge, R. M. & Clark, G. M. Tumor characteristics and clinical outcome of elderly women with breast cancer. J. Natl. 
Cancer Inst. 92, 550–556 (2000).
11
Vol.:(0123456789)
Scientific Reports |         (2021) 11:5375  | https://doi.org/10.1038/s41598-021-84825-2
www.nature.com/scientificreports/
 30. Lewis, J. H. et al. Participation of patients 65 years of age or older in cancer clinical trials. J. Clin. Oncol. 21, 1383–1389 (2003).
 31. de Glas, N. A. et al. Choosing relevant endpoints for older breast cancer patients in clinical trials: An overview of all current clinical 
trials on breast cancer treatment. Breast Cancer Res Treat 146, 591–597 (2014).
 32. Biganzoli, L. et al. Management of elderly patients with breast cancer: Updated recommendations of the International Society of 
Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 13, e148-160 (2012).
 33. INE. Indicadores demográficos básicos. Consultado el 18 de diciembre de 2020, en https ://www.ine.es/ss/Satel lite?L=es_
ES&c=INESe ccion _C&cid=12599 26380 048&p=12547 35110 672&pagen ame=Produ ctosY Servi cios/PYSLa yout (2020).
 34. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 
2817–2826 (2004).
 35. Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. 
J. Clin. Oncol. 24, 3726–3734 (2006).
 36. Stemmer, S. M. et al. Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: 
Evidence from a large prospectively designed registry. NPJ Breast Cancer 3, 33 (2017).
 37. Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379, 111–121 
(2018).
 38. Orucevic, A., Bell, J. L., King, M., McNabb, A. P. & Heidel, R. E. Nomogram update based on TAILORx clinical trial results—
Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data. Breast 46, 116–125 (2019).
Acknowledgements
The authors thank all patients and families for their participation in the MCC-Spain study, as well as all study 
centers and collaborators.
Author contributions
Study conception and design: I.G.A., T.D.S. and J.L.L. Statistical analysis: I.G.A., T.D.S. and J.L.L. Coordination 
of substudy sites, recruitment and acquisition of data: I.G.A., T.D.S., M.M., B.P.G., M.G., P.A., M.S., A.J.M.T., 
J.A.M., V.M., C.S.C., A.M.B., J.A., R.M.G., M.F.O., O.S.G., G.C.V., L.G.M., C.M.I., N.A.,. M.K., M.P. and J.L.L. 
Drafting of the manuscript: I.G.A., T.D.S. and J.L.L. Contributions to the final version of the manuscript were 
made by all authors.
Funding
Biological samples were stored at the biobanks supported by Instituto de Salud Carlos III-FEDER: Parc de 
Salut MAR Biobank (MARBiobanc) (RD09/0076/00036), ‘Biobanco La Fe’ (RD 09 0076/00021) and FISABIO 
Biobank (RD09 0076/00058), as well as at the Public Health Laboratory of Gipuzkoa, the Basque Biobank, the 
ICOBIOBANC (sponsored by the Catalan Institute of Oncology), the IUOPA Biobank of the University of 
Oviedo, and the ISCIII Biobank. SNP genotyping services were provided by the Spanish ‘Centro Nacional de 
Genotipado’ (CEGEN-ISCIII). We thank all the subjects who participated in the study and all MCC-Spain col-
laborators. This work was supported by the ‘Acción Transversal del Cancer’, approved by the Spanish Ministry 
Council on the 11th October 2007, by the Instituto de Salud Carlos III, co-founded by FEDER funds-‘a way 
to build Europe’ (Grants PI08/1770, PI08/0533, PI08/1359, PI09/00773, PI09/01286, PI09/01903, PI09/02078, 
PI09/01662, PI11/01403, PI11/01889, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, 
PI12/00715, PI12/00150, PI14/01219, PI14/00613, and PI15/00069). Support was also provided by the Fundación 
Marqués de Valdecilla (Grant API 10/09); the Junta de Castilla y León (Grant LE22A10-2); the Consejería de 
Salud of the Junta de Andalucía (2009-S0143); the Conselleria de Sanitat of the Generalitat Valenciana (Grant 
AP 061/10); the Recercaixa (Grant 2010ACUP 00310); the Regional Government of the Basque Country; the 
Consejería de Sanidad de la Región de Murcia; European Commission grants FOOD-CT-2006-036224-HIWATE; 
the Spanish Association Against Cancer (AECC) Scientific Foundation; the Catalan Government DURSI (Grant 
2014SGR647); the Fundación Caja de Ahorros de Asturias; the University of Oviedo; Societat Catalana de Diges-
tologia; and COST action BM1206 Eucolongene.
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https ://doi.
org/10.1038/s4159 8-021-84825 -2.
Correspondence and requests for materials should be addressed to I.G.-A.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2021
